Milestone Pharmaceuticals (Milestone Pharmaceuticals) EV-to-Revenue

: 72.41 (As of Today)

View and export this data going back to 2019. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Milestone Pharmaceuticals's enterprise value is $72.41 Mil. Milestone Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.00 Mil. Therefore, Milestone Pharmaceuticals's EV-to-Revenue for today is 72.41.

The historical rank and industry rank for Milestone Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

MIST' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.8 Med: 15.64 Max: 219.35
Current: 72.41

During the past 7 years, the highest EV-to-Revenue of Milestone Pharmaceuticals was 219.35. The lowest was 5.80. And the median was 15.64.

MIST's EV-to-Revenue is ranked worse than
82.25% of 1031 companies
in the Biotechnology industry
Industry Median: 7.58 vs MIST: 72.41

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), Milestone Pharmaceuticals's stock price is $1.64. Milestone Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.02. Therefore, Milestone Pharmaceuticals's PS Ratio for today is 71.30.

Milestone Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Milestone Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Milestone Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

5.49

14.74

41.69

Milestone Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue																14.74	13.35	9.64	17.57	41.69

Competitive Comparison

For the Biotechnology subindustry, Milestone Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Milestone Pharmaceuticals EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Milestone Pharmaceuticals's EV-to-Revenue falls into.

Milestone Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Milestone Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	72.406	/	1
	=	72.41

Milestone Pharmaceuticals's current Enterprise Value is $72.41 Mil.
Milestone Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00 Mil.

Milestone Pharmaceuticals (NAS:MIST) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Milestone Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1.64	/	0.023
	=	71.30

Milestone Pharmaceuticals's share price for today is $1.64.
Milestone Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.

Milestone Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Milestone Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Milestone Pharmaceuticals (Milestone Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Milestone Pharmaceuticals Inc (NAS:MIST) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, QC, CAN, H4M 2X6

Website

https://www.milestonepharma.com

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT.

Executives

Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
David Bharucha	officer: Chief Medical Officer	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Debra K. Liebert	director	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6
Richard C Pasternak	director	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M2X6
Michael John Tomsicek	director	28 OVERLOOK DRIVE, BEDFORD MA 01730
Robert James Wills	director	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jeffrey Edward Nelson	officer: Chief Operating Officer	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Paul F Truex	director	PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Fonds De Solidarite Des Travailleurs Du Quebec	10 percent owner	545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Novo Holdings A/s	10 percent owner, other: SEE REMARKS	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Amit Hasija	officer: CFO & EVP of Corp. Development	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M 2X6
Lorenz Muller	officer: Chief Commercial Officer	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6